Harrow vs Pharming
HROW and PHAR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HROW and PHAR compare
Pharming grew revenue faster over the last twelve months (26.6% versus 21.3% for Harrow).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −9.4% at Harrow.
Pharming scores higher on the StockData Score (8 against 6 for Harrow), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HROW | PHAR |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | – |
| Share price | $28.30 | $12.95 |
| Change, 1 year | −26.9% | −18.0% |
| Change, 5 years | 162% | 50.2% |
| Beta (5Y) | 1.35 | 0.55 |
| Employees | 373 | 50K |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.5× | – |
| P/B | 36.3× | – |
| FCF yield | −1.9% | – |
| Growth | ||
| Revenue growth (TTM) | 21.3% | 26.6% (better) |
| Revenue growth, 5Y average | 41.0% (better) | 12.1% |
| EPS growth, 5Y average | – | −40.8% |
| Profitability | ||
| Gross margin | 73.5% | 87.9% (better) |
| Operating margin | −2.0% | 6.9% (better) |
| Net margin | −9.4% | 0.76% (better) |
| FCF margin | −6.7% | 14.3% (better) |
| Return on equity | −74.8% | – |
| Return on invested capital | −2.1% | – |
| Financial health | ||
| Debt / equity | 10.03 | – |
| Interest coverage | −0.3× | 132× (better) |
| Current ratio | 2.29 | 2.59 (better) |
| Altman Z-score | 1.97 | – |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 57.4% | 0.32% |
| Held by insiders | 14.2% | 0.00% |
| Insider net buying, 12 months | −$9.2M | – |
| Short interest, % of float | 22.1% | – |
Go deeper
- HROW stock overview
- HROW income statement
- HROW valuation and score
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.